---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006993"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:12:53.119833+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Indivior provides FY2026 guidance: revenue $1.125B-$1.195B, Adj. EBITDA $535M-$575M

## Summary
- Total net revenue expected $1,125M-$1,195M; SUBLOCADE net revenue $905M-$945M.
- Non-GAAP operating expenses guided at $430M-$450M; adjusted EBITDA $535M-$575M.
- Completed Phase I of Indivior Action Agenda with annual operating expense savings of at least $150M.
- Shareholders approved U.K. to U.S. domicile change; expected effective Jan 26, 2026.
- Concluded DOJ matter by paying $295M in full; entered Phase II focused on accelerating growth.

## SEC filing metadata
- accession: 0001193125-26-006993
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000119312526006993/0001193125-26-006993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000119312526006993/d74661d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006993
- JSON: https://secwatch.observer/filing/0001193125-26-006993.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006993.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.